CLARITIN-D Drug Patent Profile
✉ Email this page to a colleague
When do Claritin-d patents expire, and when can generic versions of Claritin-d launch?
Claritin-d is a drug marketed by Bayer Healthcare Llc and is included in two NDAs.
The generic ingredient in CLARITIN-D is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Claritin-d
A generic version of CLARITIN-D was approved as loratadine; pseudoephedrine sulfate by PERRIGO PHARMA INTL on January 30th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLARITIN-D?
- What are the global sales for CLARITIN-D?
- What is Average Wholesale Price for CLARITIN-D?
Summary for CLARITIN-D
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 27 |
| Formulation / Manufacturing: | see details |
| Drug Sales Revenues: | Drug sales revenues for CLARITIN-D |
| What excipients (inactive ingredients) are in CLARITIN-D? | CLARITIN-D excipients list |
| DailyMed Link: | CLARITIN-D at DailyMed |
Recent Clinical Trials for CLARITIN-D
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Andover Research Eye Institute | Phase 4 |
| National Cancer Institute (NCI) | Early Phase 1 |
| Rutgers, The State University of New Jersey | Early Phase 1 |
Pharmacology for CLARITIN-D
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
US Patents and Regulatory Information for CLARITIN-D
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | CLARITIN-D | loratadine; pseudoephedrine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019670-002 | Nov 27, 2002 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bayer Healthcare Llc | CLARITIN-D 24 HOUR | loratadine; pseudoephedrine sulfate | TABLET, EXTENDED RELEASE;ORAL | 020470-002 | Nov 27, 2002 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CLARITIN-D
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | CLARITIN-D | loratadine; pseudoephedrine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019670-002 | Nov 27, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Healthcare Llc | CLARITIN-D | loratadine; pseudoephedrine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019670-002 | Nov 27, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CLARITIN-D
See the table below for patents covering CLARITIN-D around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 163059 | ⤷ Sign Up | |
| Australia | 543054 | ⤷ Sign Up | |
| Portugal | 73200 | PROCESS FOR PREPARING NOVEL ANTIHISTAMINES | ⤷ Sign Up |
| Hungary | 199138 | PROCESS FOR PRODUCING AZA DERIVATIVES OF DIHYDRO-DIBENZO /A,D/CYCLOHEPTENES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE NEW DERIVATIVE | ⤷ Sign Up |
| Philippines | 19252 | NOVEL ANTIHISTAMINE COMPOUNDS HAVING A W-ESTERIFIED CARBOXYL OR SULFONYL HETEROCYCLIC RING ATTACHED TO THREE FUSED RINGS | ⤷ Sign Up |
| Japan | H0631220 | ⤷ Sign Up | |
| Austria | 148114 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CLARITIN-D
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0152897 | C00152897/01 | Switzerland | ⤷ Sign Up | FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
| 1110543 | 08C0004 | France | ⤷ Sign Up | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
| 0152897 | 2001C/013 | Belgium | ⤷ Sign Up | PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115 |
| 0152897 | SPC/GB01/012 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
